Disc Medicine Inc Financials
This page shows Disc Medicine Inc (IRON) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Disc Medicine Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Disc Medicine Inc generates $0.86 in operating cash flow (-$93.9M OCF vs -$109.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Disc Medicine Inc earns $-226.8 in operating income for every $1 of interest expense (-$129.7M vs $572K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Disc Medicine Inc's EBITDA was -$129.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 42.3% from the prior year.
Disc Medicine Inc generated -$94.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 28.4% from the prior year.
Disc Medicine Inc reported -$109.4M in net income in fiscal year 2024. This represents a decrease of 43.1% from the prior year.
Disc Medicine Inc earned $-3.96 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 15.8% from the prior year.
Disc Medicine Inc held $192.4M in cash against $28.3M in long-term debt as of fiscal year 2024.
Disc Medicine Inc had 30M shares outstanding in fiscal year 2024. This represents an increase of 22.6% from the prior year.
Disc Medicine Inc invested $96.7M in research and development in fiscal year 2024. This represents an increase of 39.6% from the prior year.
Disc Medicine Inc invested $505K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 467.4% from the prior year.
IRON Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $50.3M+103.9% | $24.7M | N/A | $14.4M | N/A | $7.9M | N/A | $13.5M |
| SG&A Expenses | $17.4M+112.5% | $8.2M | N/A | $4.5M | N/A | $2.6M | N/A | $5.0M |
| Operating Income | -$67.7M-106.0% | -$32.9M | N/A | -$19.0M | N/A | -$10.5M | N/A | -$18.4M |
| Interest Expense | $917K | $0 | N/A | N/A | N/A | $41K | N/A | $104K |
| Income Tax | $102K-10.5% | $114K | N/A | $20K | N/A | $0 | N/A | N/A |
| Net Income | -$62.3M-134.3% | -$26.6M | N/A | -$14.1M | N/A | -$16.1M | N/A | -$18.6M |
| EPS (Diluted) | $-1.77-98.9% | $-0.89 | N/A | $-0.58 | N/A | $-16.82 | N/A | $-0.43 |
IRON Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $630.5M+26.9% | $496.8M+35.0% | $368.0M-2.3% | $376.5M+88.1% | $200.2M+88.8% | $106.0M+14.7% | $92.4M-40.6% | $155.5M |
| Current Assets | $627.2M+27.1% | $493.6M+35.0% | $365.7M-2.3% | $374.3M+88.6% | $198.5M+89.6% | $104.7M+15.7% | $90.5M-41.5% | $154.8M |
| Cash & Equivalents | $140.7M-26.9% | $192.4M-46.6% | $360.4M-2.7% | $370.5M+90.4% | $194.6M+91.3% | $101.7M+15.6% | $88.0M-41.3% | $150.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $57.1M+7.3% | $53.2M+132.5% | $22.9M+30.5% | $17.5M-25.8% | $23.6M-88.5% | $204.6M+30.6% | $156.6M+967.3% | $14.7M |
| Current Liabilities | $26.7M+14.7% | $23.3M+8.8% | $21.4M+48.7% | $14.4M-36.2% | $22.6M+1442.2% | $1.5M-89.1% | $13.4M+6.0% | $12.7M |
| Long-Term Debt | $28.9M+2.2% | $28.3M | $0 | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $573.4M+29.3% | $443.6M+28.5% | $345.1M-3.9% | $359.0M+103.3% | $176.6M+279.2% | -$98.5M-53.5% | -$64.2M-145.6% | $140.9M |
| Retained Earnings | -$449.7M-50.9% | -$298.0M-58.0% | -$188.6M-14.3% | -$165.1M-47.1% | -$112.2M+46.6% | -$210.3M-221.6% | -$65.4M+60.8% | -$166.9M |
IRON Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$47.8M-73.4% | -$27.6M-54.9% | -$17.8M-138.0% | -$7.5M+22.6% | -$9.7M+0.3% | -$9.7M-149.7% | $19.5M+221.1% | -$16.1M |
| Capital Expenditures | $26K-94.2% | $449K+14866.7% | $3K-93.3% | $45K+275.0% | $12K-36.8% | $19K+171.4% | $7K | N/A |
| Free Cash Flow | -$47.8M-70.7% | -$28.0M-57.4% | -$17.8M-136.7% | -$7.5M+22.3% | -$9.7M+0.4% | -$9.7M-149.8% | $19.5M | N/A |
| Investing Cash Flow | $49.5M+3573.9% | -$1.4M-47433.3% | -$3K+93.3% | -$45K-275.0% | -$12K+36.8% | -$19K-171.4% | -$7K | N/A |
| Financing Cash Flow | $11.6M-59.8% | $28.8M+271.2% | $7.8M+1586.5% | $460K-99.7% | $148.8M+676331.8% | $22K+100.0% | -$102.7M-8118.4% | -$1.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IRON Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.9%-4.5pp | -5.4% | N/A | -3.8% | N/A | -15.2% | N/A | -11.9% |
| Current Ratio | 23.45+2.3 | 21.17+4.1 | 17.06-8.9 | 25.96+17.2 | 8.79-62.7 | 71.49+64.8 | 6.74-5.5 | 12.23 |
| Debt-to-Equity | 0.05-0.0 | 0.06+0.1 | 0.00-0.0 | 0.05-0.1 | 0.13+2.2 | -2.08+0.4 | -2.44-2.5 | 0.10 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Disc Medicine Inc profitable?
No, Disc Medicine Inc (IRON) reported a net income of -$109.4M in fiscal year 2024.
What is Disc Medicine Inc's earnings per share (EPS)?
Disc Medicine Inc (IRON) reported diluted earnings per share of $-3.96 for fiscal year 2024. This represents a -15.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Disc Medicine Inc's EBITDA?
Disc Medicine Inc (IRON) had EBITDA of -$129.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Disc Medicine Inc have?
As of fiscal year 2024, Disc Medicine Inc (IRON) had $192.4M in cash and equivalents against $28.3M in long-term debt.
What is Disc Medicine Inc's free cash flow?
Disc Medicine Inc (IRON) generated -$94.4M in free cash flow during fiscal year 2024. This represents a -28.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Disc Medicine Inc's operating cash flow?
Disc Medicine Inc (IRON) generated -$93.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Disc Medicine Inc's total assets?
Disc Medicine Inc (IRON) had $496.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Disc Medicine Inc's capital expenditures?
Disc Medicine Inc (IRON) invested $505K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Disc Medicine Inc spend on research and development?
Disc Medicine Inc (IRON) invested $96.7M in research and development during fiscal year 2024.
How many shares does Disc Medicine Inc have outstanding?
Disc Medicine Inc (IRON) had 30M shares outstanding as of fiscal year 2024.
What is Disc Medicine Inc's current ratio?
Disc Medicine Inc (IRON) had a current ratio of 21.17 as of fiscal year 2024, which is generally considered healthy.
What is Disc Medicine Inc's debt-to-equity ratio?
Disc Medicine Inc (IRON) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Disc Medicine Inc's return on assets (ROA)?
Disc Medicine Inc (IRON) had a return on assets of -22.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Disc Medicine Inc's cash runway?
Based on fiscal year 2024 data, Disc Medicine Inc (IRON) had $192.4M in cash against an annual operating cash burn of $93.9M. This gives an estimated cash runway of approximately 25 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Disc Medicine Inc's Piotroski F-Score?
Disc Medicine Inc (IRON) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Disc Medicine Inc's earnings high quality?
Disc Medicine Inc (IRON) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Disc Medicine Inc cover its interest payments?
Disc Medicine Inc (IRON) has an interest coverage ratio of -226.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.